Current targeted therapies for LUSC harboring <i>ALK</i>, <i>ROS1</i>, or <i>EGFR</i> mutations are typically guided by protocols established for lung adenocarcinoma. This evidence concerns the gene ROS1 and lung adenocarcinoma.